News & Events

19 April 2024

A-TANGO supports World Liver Day!

The A-TANGO consortium supports World Liver Day on April 19th as we stand for the active fight against acute-on-chronic liver failure (ACLF). Currently, there are barely any treatment options for patients suffering from late-stage cirrhosis, a condition that is responsible for approximately 2.4% of deaths worldwide annually and can have various causes - including bacterial or viral infections, non-alcoholic fatty liver disease (NAFLD), or alcohol abuse. Sadly, up to 40% of patients who come to the hospital with decompensated cirrhosis / ACLF die. A-TANGO strives to increase the survival rate with G-TAK - a novel combinatorial therapy, and to decrease the burden on the national healthcare systems, which is caused by a large percentage of patients who never recover fully and require long-term care.

28 March 2024

The importance of an up-to-date strategy for successful market access in healthcare

"It's very important to keep your market access strategy up to date" and start strategic planning early for successful commercialization, following the development of a novel drug or therapy - Louise Perrault, President and CEO at IMAC - International Market Access Consulting (based in Switzerland) during yesterday's insightful Masterclass about reimbursement in healthcare. The online Masterclass "Reimbursement in Healthcare - with relevance to new therapies in cirrhosis and acute-on-chronic liver failure (ACLF)" was open to professionals in liver research, biomedicine, or healthcare, and took place on Wednesday, 27 March 2024 (see slide deck). Thank you, Louise, for this excellent learning opportunity!

9 January 2024

New podcast episode "The Patient-Doctor Relationship and Informed Consent" with Thomas Berg & Cornelius Engelmann

Explore the complexity of "The Patient-Doctor Relationship and Informed Consent" in the newest podcast episode of the “Interviews with Experts” series by Frances Hand. Join the conversation with Prof. Thomas Berg and Dr. Cornelius Engelmann as they dive into the significance of a robust doctor-patient relationship. Gain insights into the challenges surrounding informed consent amidst stressful decision-making.

Listen now on 🔗 Spotify!


More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more


  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more


Prof. Dr. Rajiv Jalan (EF CLIF)
Travessera de Gràcia 11, 7th floor
08021 Barcelona


Dr. med. Cornelius Engelmann (Charité)
Augustenburger Platz 1
13353 Berlin


concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck